-
Zero Krypton Technology Li Liping: Looking at the digital leap of pharmaceutical marketing from the two-way link between doctors and patients
Time of Update: 2021-07-06
2. Looking at the digital transition of marketing from the practice of zero krypton Based on the practical experience of digital innovation formed at the three levels of technology platform, business ecology and industry solutions, Li Liping said that to break through in pharmaceutical digital marketing, companies should make path/platform matching under the premise of clear need to solve problems, and have strategic thinking , Pre-set output for overall planning .
-
Shanghai Kaibao: The IPO application of Yizhong Pharmaceutical's Science and Technology Innovation Board, a shareholding company, has been reviewed and approved
Time of Update: 2021-07-06
On June 17, Shanghai Kaibao announced that the application for the initial public offering and listing on the Science and Technology Innovation Board submitted by the company's shareholding company Shanghai Yizhong Pharmaceutical was approved .
-
Financing continues to explode frequently, are Internet medical companies such as Kuaiyao "healthy"?
Time of Update: 2021-07-06
In 2014, Renhe Pharmaceuticals invested 5 million yuan in angel round investment to establish Dingdang Kuaiyao, starting with O2O drug delivery business .
After the change of coaching, Ping An Good Doctor launched a "comprehensive strategic upgrade" and launched four new businesses: family doctor services, consumer medical care, health malls, and health interaction and management.
-
Orsendo Biotechnology Innovation Center was unveiled in Shanghai
Time of Update: 2021-07-06
Relying on the platform technology advantages of the innovation center and regional industry collection resources, Orsondor plans to promote dozens of new products (including equipment and reagents) that meet the needs of China's local medical market in the next five years; at the same time, it plans to introduce talents, Increase local and international cooperation and other measures to further enhance the operational level in China and accelerate the construction of a "research-production-sales integrated ecosystem" in the Chinese market .
-
Ascent Pharma's Bcl-2 inhibitor APG-2575 shows strong potential in the treatment of relapsed and refractory CLL/SLL
Time of Update: 2021-07-06
A research and development company in the clinical stage dedicated to the development of innovative drugs in the treatment of tumors, hepatitis B and aging-related diseases - Ascent Pharmaceuticals announced that the American Society of Clinical Oncology (ASCO) has announced Bcl-2 inhibitors on its official website today Summary of the first human trial of lisaftoclax (APG-2575) in the treatment of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other hematological malignancies .
-
Kaili Medical brings new products to CMEF in the spring of 2021
Time of Update: 2021-07-06
Kailizhi "clear": 4K ultra-clear peak, crafted In the field of minimally invasive surgery, Kaili Medical combines its own advantages in optical design, image processing algorithms, cold light source design, and endoscope R&D and production to forcefully launch the 4K ultra-high-definition endoscopic camera system SV-M4K30, which has attracted much attention .
-
Tasly subsidiary plans to transfer some non-tradable ordinary shares of I-MAB for 250 million yuan
Time of Update: 2021-07-06
The transfer share is approximately 0.
83% of the total share capital of I-MAB, and the total equity transfer price is approximately RMB 250 million .
This transfer is conducive to improving the utilization efficiency of Tasly's biological assets and increasing investment income .
-
Cinda Bio's dual-specific fusion protein was approved for clinical use
Time of Update: 2021-07-06
The latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China shows that Cinda Biologics Class 1 new drug IBI302 has obtained the implied approval of a clinical trial and plans to develop the treatment of diabetic macular edema (DME) .
-
Yasheng Pharmaceutical is included in the MSCI China Mini Index constituent stocks
Time of Update: 2021-07-06
After being included in the Hang Seng Composite Index and other three major indexes and the Southbound Stock Connect last year, Yasheng Pharmaceutical has become a constituent stock of the MSCI China Small Cap Index this time, fully demonstrating the R&D strength, development strategy and investment value of Yasheng Pharmaceutical in the international capital market.
-
Leadstar Biotech and Gewuzhihe signed a strategic cooperation agreement on the research and development of innovative tumor drugs
Time of Update: 2021-07-06
Gewuzhihe focuses on the fields of scientific research and clinical medicine, and is committed to building a digital multi-omics platform to provide full-process innovative technology products and services for early warning and prevention of diseases, precise diagnosis, individualized treatment, and drug development .
-
Bevacizumab 1+3 pattern takes shape, Qilu, Xinda, Luye "bright move"
Time of Update: 2021-07-06
On May 26, 2021, AstraZeneca China announced that it has obtained the anti-tumor biopharmaceutical Boyouno (bevacizumab injection) from Boan Biologics, a subsidiary of Luye Pharmaceutical Group, in 21 provinces, cities, and autonomous regions in mainland China.
-
Zhendong Pharmaceutical Bicalutamide Capsules Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2021-07-06
Bicalutamide capsules have passed the quality and efficacy consistency evaluation of generic drugs .
At present, 4 domestic companies have passed the consistency evaluation, including Shanghai Zhaohui Pharmaceutical Co.
and Zhendong Pharmaceutical .
-
Kelun Pharmaceutical Omeprazole Sodium for Injection Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2021-07-06
Relevant data shows that Omeprazole Sodium for Injection is a category B product of the National Medical Insurance in 2020 and a product of the 2018 National Essential Drug List.
-
Deck Pharma and Callithera Biosciences reached an exclusive global licensing agreement
Time of Update: 2021-07-06
CB-708 is a high-efficiency and highly selective oral CD73 small molecule inhibitor, which is expected to release great potential in single-drug or combination therapy for the treatment of various tumors .
-
BeiGene will showcase its extensive clinical product pipeline at the 2021 American Society of Clinical Oncology Annual Meeting
Time of Update: 2021-07-06
BeiGene announced today that it will announce the results of multiple trials and the latest progress of its extensive clinical programs at the 2021 American Society of Clinical Oncology (ASCO) annual
-
Baike Biologics purchase day: there is no need to use the "nasal spray new crown vaccine", the shingles vaccine is the core growth point
Time of Update: 2021-07-06
Among them, the nasal spray attenuated influenza virus carrier new crown vaccine developed by Xiamen University, Hong Kong University and Beijing Wantai Company has also completed phase one and two clinical trials .
-
WuXi Biologics and OncoC4 establish exclusive CDMO partnership
Time of Update: 2021-07-06
According to the agreement, WuXi Biologics will provide integrated R&D and production services as an exclusive CDMO partner to meet the needs of OncoC4's biological drugs from early research, preclinical to commercialization .
-
Merck announced the completion of the spin-off of Ogalon
Time of Update: 2021-07-06
It is expected that the spin-off will enable Merck to focus more on the development of key growth pillars and achieve higher revenue and earnings per share growth rates.
In this spin-off, Merck received approximately US$9 billion in allotments from Ogalon .
-
PICC Executive Director and Vice President Xie Yiqun resigns at the age
Time of Update: 2021-07-06
Xie Yiqun resigned from the position of executive director, vice president and member of the strategy and investment committee of the board of directors of the company due to his age, and his resignation will take effect on June 15, 2021 .
-
BeiGene announced that the FDA has accepted the application for new indications of BeiGene for marginal zone lymphoma
Time of Update: 2021-07-06
S. Food and Drug Administration (FDA) has accepted Baiyueze® (Zebutinib) for the treatment of adult marginal zone lymphoma (MZL) patients who have previously received at least one CD20-directed therapy.
